Literature DB >> 9219409

Warfarin anticoagulation in primary care: a regional survey of present practice and clinicians' views.

H Rodgers1, M Sudlow, R Dobson, R A Kenny, R G Thomson.   

Abstract

The demand for anticoagulation services is rising. Warfarin anticoagulation has been shown to reduce the risk of stroke in patients with non-valvular atrial fibrillation by 68%. This raises issues about how services are best organized to initiate and monitor anticoagulation in this potentially large group of patients. We report the results of a regional postal survey undertaken to describe the views of general practitioners and consultants regarding warfarin anticoagulation in light of this potentially high increase in demand.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9219409      PMCID： PMC1313007     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


  5 in total

1.  Introduction of computer assisted control of oral anticoagulation in general practice.

Authors:  M J Galloway; J J Foggin; S Dixon
Journal:  J Clin Pathol       Date:  1995-12       Impact factor: 3.411

2.  Service provision and use of anticoagulants in atrial fibrillation.

Authors:  C M Sudlow; H Rodgers; R A Kenny; R G Thomson
Journal:  BMJ       Date:  1995-08-26

3.  Comparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic.

Authors:  J P Pell; B McIver; P Stuart; D N Malone; J Alcock
Journal:  Br J Gen Pract       Date:  1993-04       Impact factor: 5.386

Review 4.  ABC of atrial fibrillation. Atrial fibrillation in general and hospital practice.

Authors:  G Y Lip; D G Beevers; J R Coope
Journal:  BMJ       Date:  1996-01-20

Review 5.  Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice.

Authors:  K G Sweeney; D P Gray; R Steele; P Evans
Journal:  Br J Gen Pract       Date:  1995-03       Impact factor: 5.386
  5 in total
  10 in total

1.  Policy dilemmas for oral anticoagulation management.

Authors:  D A Fitzmaurice; J P Raftery; S Bryan
Journal:  Br J Gen Pract       Date:  2000-10       Impact factor: 5.386

2.  Anticoagulation for patients with atrial fibrillation. Editorial may have overinterpreted data.

Authors:  N Dudley
Journal:  BMJ       Date:  2000-09-09

3.  Oral anticoagulation monitoring.

Authors:  D Macaulay
Journal:  Br J Gen Pract       Date:  1997-11       Impact factor: 5.386

4.  Non-valvular atrial fibrillation (NVAF)

Authors:  E Roderick; J Cox
Journal:  Br J Gen Pract       Date:  1997-10       Impact factor: 5.386

5.  Physician decision making in anticoagulating atrial fibrillation: a prospective survey of a physician notification system for atrial fibrillation detected on cardiac implantable electronic devices of patients at increased risk of stroke.

Authors:  Justin M Cloutier; Clarence Khoo; Brett Hiebert; Anthony Wassef; Colette M Seifer
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-04

Review 6.  Anticoagulants for atrial fibrillation: why is the treatment rate so low?

Authors:  Thomas A Buckingham; Robert Hatala
Journal:  Clin Cardiol       Date:  2002-10       Impact factor: 2.882

7.  Randomised trial of two approaches to screening for atrial fibrillation in UK general practice.

Authors:  Stephen Morgan; David Mant
Journal:  Br J Gen Pract       Date:  2002-05       Impact factor: 5.386

8.  Importance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paper.

Authors:  N Dudley
Journal:  Qual Health Care       Date:  2001-09

9.  Development and description of a decision analysis based decision support tool for stroke prevention in atrial fibrillation.

Authors:  Richard Thomson; Angela Robinson; Jane Greenaway; Philip Lowe
Journal:  Qual Saf Health Care       Date:  2002-03

10.  Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy.

Authors:  D Ferro; L Loffredo; L Polimeni; F Violi
Journal:  Intern Emerg Med       Date:  2007-03-31       Impact factor: 3.397
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.